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Association of Disease Location and TreatmentWith Survival
in Diffuse Large B-Cell Lymphoma of the Eye
andOcular Adnexal Region
Aseef H. Ahmed, MS; C. Stephen Foster, MD; Carol L. Shields, MD
IMPORTANCE Primary diffuse large B-cell lymphoma (DLBCL) of the ocular region is rare, and
the utility of surgery and radiation therapy remains unresolved.
OBJECTIVE To explore the clinical characteristics and determine factors associated with
overall survival in primary vitreoretinal lymphoma (PVRL) and ocular adnexal (OA)–uveal
DLBCL.
DESIGN, SETTING, AND PARTICIPANTS This retrospective analysis included 396 patients with
ophthalmic DLBCL from January 1, 1973, through December 31, 2014, using the Surveillance,
Epidemiology, and End Results database. Themedian follow-up was 39.0months
(interquartile range, 5.1-72.9months). All patients diagnosed with primary DLBCL of the eye
or retina (PVRL) or the eyelid, conjunctiva, choroid, ciliary body, lacrimal gland, or orbit
(OA-uveal lymphoma) were included. Patients diagnosed at autopsy or with additional
neoplastic disease were excluded.
MAIN OUTCOMES ANDMEASURES Patient demographic characteristics, disease location,
treatment modalities, and overall survival.
RESULTS Forty-seven patients with PVRL (24 women [51.1%] and 23men [48.9%]) and 349
with OA-uveal DLBCL (192 women [55.0%] and 157men [45.0%]) had a similar mean (SD)
age at diagnosis (69.6 [12.3] vs 66.1 [17.7] years). No difference in the use of surgery or
radiation therapy by location was found. For all PVRL and OA-uveal DLBCL, a Cox
proportional hazards regressionmodel affirmed that age older than 60 years was associated
with increased risk for death (hazard ratio [HR], 2.7; 95% CI, 1.9-4.0; P < .001). Gross total
resection was associated with a decreased risk for death (HR, 0.5; 95% CI, 0.3-0.9; P = .04),
whereas radiation therapy was not. The 5-year overall survival among patients with PVRL was
41.4% (SE, 8.6%); among those with OA-uveal DLBCL, 59.1% (SE, 2.8%; Mantel-Cox test,
P = .007). Median overall survival was lower in PVRL (38.0months; 95% CI, 14.2-61.8
months) than in OA-uveal DLBCL (96.0months; 95% CI, 67.3-124.7 months; Mantel-Cox test,
P = .007). In addition, median overall survival in ophthalmic-only disease was higher (84.0
months; 95% CI, 63.2-104.8months) than that in primary DLBCL that occurred outside the
central nervous system and ophthalmic regions (46.0months; 95% CI, 44.4-47.6months;
Mantel-Cox test, P < .001).
CONCLUSIONS AND RELEVANCE The 5-year survival in PVRL vs OA-uveal DLBCL differed by
17.7%, and overall survival was greater in ophthalmic DLBCL than in DLBCL located outside
the central nervous system and ophthalmic regions. Younger age (60 years) and gross total
resection were associated with increased survival.
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D iffuse largeB-cell lymphoma(DLBCL) isacancerofma-ture B lymphocytes. It is the most common subtypeof non–Hodgkin lymphoma, representing 25% of
cases.1 In the United States, this malignant neoplasm has an
incidence of 7 cases per 100000 persons per year and occurs
most frequently in white (85.5%) and male (56.0%)
individuals.2 The slightmale predominance ofDLBCL is simi-
lar to that of other non–Hodgkin lymphoma.2
TheoriginofDLBCLisnodal inapproximately58%ofcases,
extranodal in 42%, and extranodal extramedullary in 40%.3,4
Diffuse large B-cell lymphoma can occur in various intraocu-
lar and ocular adnexal (OA) compartments, including the vit-
reous, retina, optic nerve, and subretinal pigment epithelium
(primaryvitreoretinal lymphoma[PVRL]), and intheuvea,con-
junctiva, orbit, and eyelid (OA-uveal DLBCL).
The PVRL subtype is a primary central nervous system
(CNS) lymphoma that can manifest in the eye, with com-
monlypreceding, simultaneous, or sequential involvementof
the CNS.5,6 The intraocular malignant neoplasm involves the
vitreous most commonly and the retina, subretinal pigment
epithelium, and optic nerve.7 The incidence of primary CNS
lymphomafrom2005through2009was0.45per 100000per-
son-years, and 15% to 25% of patients with primary CNS lym-
phoma are estimated to manifest intraocular involvement
(PVRL).5,8,9 Most cases of PVRL prove to be DLBCL.10-13 Ow-
ing to the rarity of PVRL and the small, heterogeneous study
populations, the specific prognosis is somewhat unclear. One
study of patients with PVRL demonstrated a 5-year cumula-
tive survival rate of 35%among thosewith additional CNS ex-
tension and 68% among those without CNS extension.14
Primary DLBCL can also occur in the orbit, OA, choroid,
ciliary body, and iris, collectively termedOA-uveal regions.15-17
Orbital lymphoma is commonand represents themost preva-
lent malignant orbital tumor in older adults.18 Patients with
orbital lymphoma generally present with painless, progres-
sive orbital fullness or proptosis, dysmotility, and ptosis,
whereas eyelid lymphoma manifests as a nontender, pal-
pable mass, often with ptosis. By contrast, conjunctival
lymphoma appears as a nontender, salmon-colored mass
hidden in the fornix and occasionally with choroidal
involvement.19 Unlike PVRL, OA-uveal lymphoma does not
generally extend into the CNS unless left untreated.17,20 Dif-
fuse large B-cell lymphoma represents 8% of all OA lym-
phomaand3%ofall conjunctival lymphomaand ismore likely
to have systemic involvement and to be aggressive.15,21 Five-
year overall survival rates in OA-uveal DLBCL, including all
stages fromlocalized tosystemic involvement, range from20%
to 36%.19,20,22
The management for these 2 different clinical entities
has limited to no overlap. Treatment of PVRL consists of
high-dose vitreous methotrexate sodium, which forms the
backbone of chemotherapy, often in combination with ritux-
imab. Lymphoma of the CNS needs to be considered and
examined.23,24 Radiotherapy is the preferred treatment in
some centers but carries risks for radiation-related cataract,
retinopathy, and optic neuropathy as well as nontreatment
of potential CNS disease.25,26 For OA lymphoma, initial sur-
gical resection for biopsy confirmation, followed by chemo-
therapy and/or radiotherapy, is performed.19 For uveal lym-
phoma, confirmation is done with fine-needle aspiration
biopsy, and treatment with radiotherapy, chemotherapy,
and/or rituximab is administrered.16
Therelativepresentation, treatment,andoutcomesofoph-
thalmic DLBCL are not well described in a large cohort. Thus,
the purpose of this study was to delineate these features and
overall survival characteristics using a national registry data-
base, with focus on PVRL vs OA-uveal DLBCL.
Methods
We queried the November 2016 submission of the National
Cancer Institute’s Surveillance, Epidemiology, and End Re-
sults (SEER) database for diffuse large B-cell lymphoma
(DLBCL) (International Classification of Diseases for Oncology
code 3 9680/3) diagnosed between January 1, 1973, and De-
cember 31, 2014, occurring primarily in the eye, not other-
wise specified (NOS), and the retina to represent PVRL.Theda-
tabasewasalsoqueried forDLBCLthatoccurredwithaprimary
site of the eyelid, conjunctiva, choroid, ciliary body, lacrimal
gland, andorbit, jointly representingOA-uvealdisease.Finally,
DLBCL that occurred in non-CNS and nonophthalmic regions
was queried. This studywas approved by the institutional re-
view board of Wills Eye Hospital, which waived the need for
informed consent for use of data from the public registry.
Cases diagnosed at autopsy and cases involving second-
ary cancers were excluded. When available, data were ex-
tracted on patient age, sex, race, AnnArbor stage (range, I-IV,
with I indicating a single lymph node group; IV, multiple
extranodal sites or lymph nodes), surgical resection, radia-
tion therapy, survival time, andoutcome (alive or deaddue to
any cause at the end of follow-up). Data on use of chemo-
therapy and the International Prognostic Index27 were not
available for analysis. Tumorgradeandhistologic trait databe-
yond diagnostic confirmation were sparse or unavailable.
Treatment designations considered to be surgical resec-
tion included partial resection and/or excision, gross total re-
section, surgery NOS, and local tumor destruction, which
consisted of laser ablation or electrocautery. Treatment with
external beam radiation represented radiation therapy.
Key Points
Question Which factors influence overall survival in ophthalmic
diffuse large B-cell lymphoma?
Findings In this analysis of 396 patients with ophthalmic diffuse
large B-cell lymphoma using the Surveillance, Epidemiology, and
End Results database, older age (>60 years) was associated with
increased risk for death, and gross total resection was associated
with a decrease in this risk. A primary vitreoretinal location was
associated with lower overall survival than an ocular adnexal–uveal
location, and overall survival was greater in ophthalmic disease
than non–central nervous system and nonophthalmic disease.
Meaning Patient age, disease location, and surgical excisionmay
influence overall survival in ophthalmic diffuse large B-cell
lymphoma.
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We conducted a descriptive statistical analysis to deter-
mine demographic, tumor, and treatment characteristics, in-
cluding 2-tailed t test, analysis of variance, and the Kruskal-
Wallis test with a post hoc Dunn-Bonferroni approach. A Cox
proportional hazards regression analysis was conducted to
determine factors associated with death, controlling for age,
sex, race, treatmentwithradiation, treatmentwithsurgery,and
disease location. Age was dichotomized (≤60 vs >60 years)
as recommendedby the International Prognostic Indexmodel
for non–Hodgkin lymphoma.27 Lateralitywas not included as
a covariate because of the low overall proportion of bilateral
disease.
We conducted Kaplan-Meier survival analyses to deter-
mine overall survival and to compare survival by DLBCL dis-
ease location. Analyses were conducted with SPSS software
(version 23.0; IBM), with P < .05 indicating significance.
Results
Forty-seven patients with PVRL had a mean (SD) age at diag-
nosis of 69.6 (12.3) years, with a female predominance (24
women[51.1%]and23men[48.9%]; sexratio, 1.04).Threehun-
dred forty-nine patients with primary OA-uveal DLBCL had a
mean (SD) age at diagnosis of 66.1 (17.7) years that was not
significantlydifferent frompatientswithPVRL (t test,P = .18).
Ocular adnexal–uveal DLBCL also had a female predomi-
nance (192 women [55.0%] and 157 men [45.0%]; sex ratio,
Table 1. Characteristics of Primary DLBCL of the Eye andOA Regionsa
Characteristic
OA-Uveal Lymphoma
PVRL
(n = 47) P Valueb
Eyelid
(n = 28)
Conjunctiva
(n = 26)
Lacrimal Gland
(n = 27)
Orbit
(n = 239)
Ciliary Body
(n = 21)
Choroid
(n = 8)
Patient
Age, mean (SD), y 68.1 (17.4) 61.6 (23.1) 61.2 (19.5) 67.1 (17.2) 63.3 (10.7) 68.4 (7.9) 69.6 (12.3) .26
Age ≤60 y 10 (35.7) 12 (46.2) 14 (51.9) 83 (34.7) 8 (38.1) 1 (12.5) 9 (19.1)
.07
Age >60 y 18 (64.3) 14 (53.8) 13 (48.1) 156 (65.3) 13 (61.9) 7 (87.5) 38 (80.9)
Sex ratio, female to male 1.00 2.25 2.00 1.03 3.20 1.67 1.04 .13
Race
White 24 (85.7) 22 (84.6) 24 (88.9) 206 (86.2) 17 (81.0) 8 (100) 39 (83.0)
.86
Black 1 (3.6) 2 (7.7) 1 (3.7) 14 (5.9) 0 0 0
Asian/Pacific Islander 1 (3.6) 1 (3.8) 1 (3.7) 16 (6.7) 4 (19.0) 0 6 (12.8)
Native American or Alaskan 0 0 0 0 0 0 0
Unknown 2 (7.1) 1 (3.8) 1 (3.7) 3 (1.3) 0 0 2 (4.3)
Disease
Laterality
Unilateral 28 (100) 24 (92.3) 27 (100) 230 (96.2) 16 (76.2) 6 (75.0) 39 (83.0)
<.001Bilateral 0 2 (7.7) 0 5 (2.1) 5 (23.8) 2 (25.0) 8 (17.0)
Unknown 0 0 0 4 (1.7) 0 0 0
Ann Arbor stagec
I 19 (67.9) 19 (73.1) 17 (63.0) 121 (50.6) 15 (71.4) 5 (62.5) 30 (63.8)
.41
II 2 (7.1) 0 2 (7.4) 20 (8.4) 1 (4.8) 0 3 (6.4)
III 0 3 (11.5) 3 (11.1) 47 (19.7) 0 0 0
IV 2 (7.1) 3 (11.5) 2 (7.4) 32 (13.4) 4 (19.0) 2 (25.0) 6 (12.8)
Unknown 5 (17.9) 1 (3.8) 3 (11.1) 19 (7.9) 1 (4.8) 1 (12.5) 8 (17.0)
Treatment
Surgery
None or biopsy only 10 (35.7) 14 (53.8) 15 (55.6) 133 (55.6) 12 (57.1) 3 (37.5) 25 (53.2)
.14
Partial resection or excision 8 (28.6) 12 (46.2) 10 (37.0) 75 (31.4) 5 (23.8) 2 (25.0) 11 (23.4)
Gross total resectiond 1 (3.6) 0 0 7 (2.9) 3 (14.3) 1 (12.5) 3 (6.4)
Surgery NOS 3 (10.7) 0 0 6 (2.5) 1 (4.8) 2 (25.0) 2 (4.3)
Local tumor destructione 2 (7.1) 0 1 (3.7) 5 (2.1) 0 0 1 (2.1)
Unknown 4 (14.3) 0 1 (3.7) 13 (5.4) 0 0 5 (10.6)
Radiation therapy
None 10 (35.7) 13 (50.0) 15 (55.6) 99 (41.4) 11 (52.4) 3 (37.5) 19 (40.4)
.61Administered 17 (60.7) 13 (50.0) 12 (44.4) 133 (55.6) 9 (42.9) 5 (62.5) 25 (53.2)
Unknown 1 (3.6) 0 0 7 (2.9) 1 (4.8) 0 3 (6.4)
Abbreviations: DLBCL, diffuse large B-cell lymphoma; NOS, not otherwise
specified; OA, ocular adnexal; PVRL, primary vitreoretinal lymphoma.
a Unless otherwise indicated, data are expressed as number (percentage) of
patients. Percentages have been rounded andmay not total 100.
bCalculated using 1-way analysis of variance or Kruskal-Wallis test.
c I indicates single lymph node group; IV, multiple extranodal sites or lymph
nodes.
d Includes eye enucleation.
e Includes laser ablation and electrocautery.
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1.22),withnodifferencebasedon location (Kruskal-Wallis test,
P = .13) (Table 1). The median follow-up was 39.0 months
(interquartile range, 5.1-72.9 months).
When we compared PVRL and separate locations of OA-
uveal disease, we found no difference in age (analysis of vari-
ance, P = .26) and proportion of patients older than 60 years
(Kruskal-Wallis test, P = .07) (Table 1). We found no differ-
ence in patient race by location of disease, with each sub-
group having mostly white patients (Kruskal-Wallis test,
P = .86) (Table 1). As expected, most cases had a unilateral
presentation. A higher proportion of bilateral disease oc-
curredwithprimaryDLBCLof the ciliarybody (5of 21 [23.8%];
Kruskal-Wallis test,P < .001) comparedwith nopatientswith
primaryDLBCLof theeyelidandlacrimalgland(posthocDunn-
Bonferroni approach, P = .02) and orbit (5 of 239 [2.1%]; post
hoc Dunn-Bonferroni approach, P = .01). We found no differ-
ence in proportions of Ann Arbor stage among disease loca-
tions. Data on extension into the CNS specifically were not
available.
Among all locations of disease, treatment approaches in-
cluded surgery, radiation therapy, both, or neither. We found
nodifference in theuseor typeof surgeryby location (Kruskal-
Wallis,P = .14) andnodifference in theuseof radiation therapy
(Kruskal-Wallis, P = .61) (Table 1). Data on chemotherapy use
were not available for analysis.
ACoxproportional hazard regressionmodel revealed that
increasedageatdiagnosis (dichotomizedat≤60and>60years)
wasassociatedwith increased risk fordeath (hazard ratio [HR],
2.7; 95% CI, 1.9-4.0; P < .001). Patient sex and race were not
associatedwith death. Ann Arbor stages and disease location
were also not associated with death in this model. Although
all surgical interventionswere associatedwith decreased risk
for death, most were not determinants. However, gross total
resection, including eye enucleation and orbitotomy, was as-
sociatedwith a decreased risk for death (HR, 0.5; 95%CI, 0.3-
0.9; P = .04). The use of radiation therapywas not associated
with survival (Table 2).
Kaplan-Meier survival analyses revealed that overall
survival differed by location (Table 3 and Figure 1). Patients
with PVRL had a 5-year overall survival rate of 41.4% (SE,
8.6%), and those with OA-uveal disease had a 5-year overall
survival rate of 59.1% (SE, 2.8%) (Mantel-Cox test, P = .007).
When we compared overall survival by Ann Arbor stages in
PVRL, stage I had a median overall survival of 43.0 months
(95% CI, 14.3-71.7 months); stages II to IV, 75.0 months (95%
CI, 0-197.0 months) (Mantel-Cox test, P = .17). Median over-
all survival was higher for stage I (129.0 months; 95% CI,
95.0-163.0 months) than for stages II to IV (77.0 months;
95% CI, 47.1-106.9 months) in OA-uveal disease (Mantel-Cox
test, P = .02).
Median overall survivalwas lower in PVRL (38.0months;
95% CI, 14.2-61.8 months) than in OA-uveal disease (96.0
months;95%CI,67.3-124.7months;Mantel-Cox test,P = .007)
(Figure 2). In addition,median overall survival in ophthalmic
(PVRL, uveal, and OA) diseasewas higher (84.0months; 95%
CI, 63.2-104.8 months) than in primary DLBCL that occurred
outside the CNS and ophthalmic regions (46.0 months; 95%
CI, 44.4-47.6 months; Mantel-Cox test, P < .001).
Discussion
The present study represents a comprehensive analysis of
primary DLBCL of the eye and OA regions and confirms pre-
Table 2. Cox Proportional Hazards RegressionModel of Factors
AssociatedWith Overall Survival of Primary DLBCL of the Eye
andOA Regions
Characteristic
Hazard Ratio
(95% CI) P Valuea
Patient
Age ≤60 y 1 [Reference] NA
Age >60 y 2.7 (1.9-4.0) <.001
Sex
Female 1 [Reference] NA
Male 0.9 (0.7-1.2) .49
Race
White 1 [Reference] NA
Black 4.2 (0.6-32.4) .16
Asian or Pacific Islander 5.1 (0.6-46.4) .15
Unknown 4.4 (0.5-35.2) .16
Disease
Ann Arbor stageb
I 1 [Reference] NA
II 0.9 (0.5-1.5) .57
III 0.8 (0.4-1.6) .53
IV 0.7 (0.4-1.5) .40
Unknown 1.7 (0.9-3.1) .08
Location
Eyelid 1 [Reference] NA
Conjunctiva 1.9 (0.5-6.9) .33
Lacrimal gland 2.3 (0.6-8.9) .21
Orbit 1.0 (0.2-3.9) .96
Ciliary body 1.9 (0.6-6.2) .31
Choroid 2.5 (0.7-8.7) .14
Vitreoretinal 1.0 (0.2-3.9) .96
Treatment
Surgery
None or biopsy only 1 [Reference] NA
Partial resection or excision 0.6 (0.3-1.1) .07
Gross total resectionc 0.5 (0.3-0.9) .04
Surgery NOS 0.5 (0.2-1.2) .11
Local tumor destructiond 0.8 (0.4-1.8) .58
Unknown 0.6 (0.2-1.5) .28
Radiation therapy
None 1 [Reference] NA
Administered 1.2 (0.5-2.7) .65
Unknown 0.8 (0.4-1.8) .59
Abbreviations: DLBCL, diffuse large B-cell lymphoma; NA, not applicable;
NOS, not otherwise specified; OA, ocular adnexal.
a Calculated using Cox proportional hazards regression.
b I indicates single lymph node group; IV, multiple extranodal sites or lymph
nodes.
c Includes eye enucleation.
d Includes laser ablation and electrocautery.
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vious knowledge of this disease. Primary vitreoretinal lym-
phomaandOA-uveal diseaseoccurmost often in the sixthand
seventh decades of life. Incidence is generally higher among
women, an inverse of non–Hodgkin lymphoma found inother
sites, for which men predominate.19 This malignant neo-
plasm generally demonstrates a poor prognosis. From the
perspective of location, the prognosis of primary DLBCL dif-
fers.We foundthe lowestmedianoverall survival forPVRLand
ciliary bodydisease,whereas theoutlook for conjunctival and
lacrimal gland disease was better. Disease of the orbit and
eyelid had an intermediate prognosis. Poor prognosis for cili-
ary body disease was likely related to its increased bilateral
manifestation.
A Cox proportional hazards regression model demon-
strated that age greater than 60 years was associated with an
increased risk for death. This association is well established
in the non–Hodgkin lymphoma literature, and this cutoff is
also a component of the International Prognostic Index.27 In
our model, Ann Arbor stage and disease locations were not
determinants. However, Kaplan-Meier survival analysis dem-
onstrated a difference for OA-uveal disease and not for PVRL.
This effect of staging has been demonstrated previously for
primary DLBCL of the ocular adnexa, including for overall
and disease-specific survival.20,22 The significance of the
Ann Arbor staging system does not apply to primary CNS
lymphoma, a subtype of which is PVRL, which corroborates
these results.28
Decreased risk fordeathwasassociatedwithsurgical treat-
ment consisting of gross total resection, including eye enucle-
ation. The role of surgery for the treatment of PVRL or OA-
uveal DLBCL continues to be explored.19 In a retrospective
study of 34 patients with DLBCL of the ocular adnexa, only 1
was treatedwith complete surgical resection.20 Surgery as the
only treatment modality for orbital lymphoma is not typi-
cally used because of the difficulty with visualization of
the entire infiltrating mass for resection and the concern for
Figure 1. Overall Cumulative Survival for Primary Diffuse Large B-Cell Lymphoma (DLBCL)
of the Eye andOcular Adnexal Regions
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Table 3. Overall Cumulative andMedian Survival of Primary DLBCL of the Eye andOA Regions After Diagnosis
Location
Survival Rate, Overall Cumulative (SE)a Survival,
Median (SE),
mo1 y 2 y 5 y 10 y
Eyelid 85.6 (6.7) 74.4 (8.4) 55.3 (9.6) 45.3 (10.2) 83 (56.1)
Conjunctiva 88.0 (6.5) 88.0 (6.5) 88.0 (6.5) 58.8 (14.9) 123 (23.1)
Lacrimal gland 92.6 (5.0) 92.6 (5.0) 68.4 (10.3) 58.6 (12.6) (Not reached)
Orbit 79.5 (2.6) 71.8 (3.0) 56.3 (3.4) 45.1 (4.0) 86 (20.1)
Ciliary body 84.2 (8.4) 60.2 (11.8) 44.6 (13.0) 29.7 (14.9) 46 (19.2)
Choroid 64.3 (21.0) 64.3 (21.0) 32.1 (25.0) 32.1 (25.0) 78 (38.2)
PVRL 79.5 (6.1) 64.3 (7.5) 41.4 (8.6) 15.8 (7.8) 38 (12.1)
Abbreviations: DLBCL, diffuse large
B-cell lymphoma; OA, ocular adnexal;
PVRL, primary vitreoretinal
lymphoma.
a Indicates cumulative proportion
surviving at each time.
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residual tumor with the risk for recurrence.29 More com-
monly, surgery is performed first for biopsydocumentationor
resection to prevent morbidity, and the backbone of treat-
ment is chemotherapy and/or radiation therapy.30 The use of
surgery for PVRL is not well studied.
Radiation therapyhasdemonstrated a role indisease con-
troloforbital lymphomaandPVRL.25,31Ourmodeldidnotdem-
onstrate that radiation therapy influences the risk for death;
however, the SEER database does not differentiate between
palliative and goal-directed radiation therapy. The relative
efficacy of radiation therapy and chemotherapy continues to
be debated for intraocular lymphoma.32 Although radiation
therapy is associatedwithcataract formation, retinopathy, and
neuropathy,anintensive induction-consolidation-maintenance
regimenofmethotrexatechemotherapy is alsoassociatedwith
risk for keratopathy,maculopathy, anddrug resistance.25,33,34
This riskhas ledtotherecommendationof fewerchemotherapy
cycleswith longer intervals and the addition of rituximab as a
less toxic approach.24,32Whether ocular therapy affects over-
all survival is still unclearowing to the lackof randomizedclini-
cal trials.25
This study affirms that PVRL has a comparatively poorer
prognosis thanOA-uvealdiseaseusinganationaldatabase.This
finding is likelyattributable to thecommonassociationofPVRL
with CNS disease. Themost common cause of death in these
cases isCNSlymphoma.25Ocularadnexal–uveal lymphomacan
also extend to the CNS; however, the likelihood is relatively
low, especially in unilateral disease.17,20 The median overall
survival forPVRL (38.0months;95%CI, 14.2-61.8months)was
similar to that of 31months reportedpreviously.35 PrimaryDL-
BCLof theophthalmic regionswasdocumented tohave abet-
ter prognosis than primary DLBCL of non-CNS and nonoph-
thalmic regions. This finding is possibly attributable to extent
of disease because primary DLBCL of the ophthalmic regions
is often localized at presentation.
Limitations
The rarity of primary DLBCL of the eye and OA regions pre-
cludes prospective studies with high statistical power, mak-
ing retrospective studies, such as this one, the next best ap-
proach.Retrospectivedatahave intrinsic reportingbiases. The
SEERdatabase ishistoricallyasurgery-baseddatabase,andsur-
gerydoesnotplayaprominent role in thisdisease.Dataonche-
motherapy use are lacking, and because chemotherapy plays
an important role in management, such data may have theo-
retically improved the predictive model in this study.
The SEER database does not have a primary site code for
vitreous. The site designated eye, NOSwas deemed to refer to
thevitreousbecauseofseparatecodes foradnexal regions.Data
on the International Prognostic Index, serum lactatedehydro-
genase level, centroblastic vs immunoblastic histopathologic
findings, and recurrence were not available.36 Of impor-
tance, the natural history of the disease in each case was not
thorough.20 The specific degree of extension of disease into
the CNS, which is an important prognosticator for PVRL, was
unknown.25
Conclusions
Primary ophthalmic DLBCL can be classified into PVRL or
OA-uveal subtypes,withbothgroupsof patients presenting at
a later age. Prognosis differs by disease location andwas poor
with PVRL, with a 58.6% mortality rate by 5 years, whereas
OA-uveal DLBCL demonstrated a 40.9% mortality rate by 5
years. Patients with PVRL andOA-uveal DLBCL subtypes had
greater overall survival compared with DLBCL located out-
side the CNS and ophthalmic regions.
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